Chemotherapy Compounding Payment Scheme (CCPS)
Page last updated: 5 September 2017
The Australian Government supports Australians to access Pharmaceutical Benefits Scheme (PBS) chemotherapy medicines through the Efficient Funding of Chemotherapy (EFC) arrangements. Under the Sixth Community Pharmacy Agreement (6CPA), $372 million is provided for chemotherapy compounding fees.
A new two-tiered fee structure for chemotherapy compounding fees was implemented from 1 July 2015:
- $60 is paid* where the compounder holds a manufacturing licence from the Therapeutic Goods Administration (TGA) for the relevant compounding site, as broken down into the following components:
- a $40 compound fee paid to approved suppliers through the PBS; and
- a $20 additional compound fee paid directly to TGA-licensed compounders through the CCPS Administration Agency; or
- $40 is paid* to approved suppliers through the PBS where the compounder does not hold a manufacturing licence from the TGA for the relevant compounding site.
* Per eligible (PBS) (EFC) item.
This fee structure recognises the additional costs associated with TGA licensing and the greater focus on the quality use of medicines that it provides.
PBS claiming arrangements for the CCPS
To support the introduction of the new fees, a staged implementation of two new fields within the PBS Online claiming system has been undertaken.
From 1 September 2016, approved pharmacists, approved medical practitioners and approved hospital authorities (approved suppliers) will need to provide additional information when claiming eligible EFC items through the PBS. New data fields within the PBS Online for EFC claims will include:
- a field to identify the compounder of the item (compounder ID); and
- a field for a serialised infusion identifier, which will be automatically generated by PBS dispensing software for each infusion (infusion ID).
From 1 December 2017, inclusion of the compounder ID field within an EFC claim will be mandatory. Claims for eligible EFC items submitted through PBS Online without a valid compounder ID from this date will not be paid.
Chemotherapy compounders (both TGA-licensed and non-licensed) will need to apply to the CCPS Administration Agency to obtain a compounder ID for each compounding site within their organisation. Compounders will need to provide approved suppliers with the relevant compounder ID in respect of each eligible PBS EFC item provided.
To apply for a compounder ID for a compounding site, compounders will need to complete the Chemotherapy Compounder ID Allocation Form (PDF 153KB) - (Word 67KB) and return it to the CCPS Administration Agency via email (email@example.com) or via post at the following address:
CCPS Administration Agency
Australian Healthcare Associates
Locked Bag 32005
COLLINS STREET EAST VIC 8003
Chemotherapy compounders applying to the CCPS Administration Agency for a compounder ID should also view the Australian Privacy Principle 5 Notification (PDF 52KB) - (Word 23KB) that relates to the collection of the information requested within the Chemotherapy Compounder ID Allocation Form.
The purpose of these changes is to support a streamlined payment system for the two-tiered fee structure. The additional data fields will also enable a better understanding of the scope of chemotherapy compounding in Australia, and provide transparency of compounding activity funded through the PBS.
For further information on these changes, please refer to the Factsheet: EFC changes to PBS claiming requirements.